Trial Information
Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma
Inclusion Criteria:
- To be diagnosed as metastatic renal cell carcinoma
- Previous cytokine therapy
- To sign informed consent form (ICF)
Exclusion Criteria:
- Patients not willing to sign informed consent form or who withdraw their consent
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Duration of treatment: from start of tyrosine kinase inhibitor treatment to permanent discontinuation of the product
Outcome Time Frame:
After 2 years
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Turkey: Ministry of Health General Directorate of Pharmaceuticals and Pharmacy
Study ID:
16263
NCT ID:
NCT01585974
Start Date:
November 2012
Completion Date:
December 2014
Related Keywords:
- Renal Cell Carcinoma
- Renal Cell Carcinoma
- TKI
- Turkey
- Observational
- Carcinoma
- Carcinoma, Renal Cell